Project Grant R01HL185244
- The National Heart, Lung, and Blood Institute awarded the University of Washington $2.815 million on September 24, 2025, under CFDA 93.837 (Cardiovascular Diseases Research) to conduct proteomic and genomic discovery of molecular targets linked to atrial cardiopathy-related cardiovascular outcomes. The award funds research using proteomics and genomic methods across primary and secondary prevention populations to identify novel proteins that may serve as causal risk factors for atrial...
- The National Institute of General Medical Sciences awarded the University of Washington $380,371 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop computational methods that infer cellular history from single-cell sequencing data, enabling analysis of disease progression in tissues that cannot be sampled longitudinally, such as the brain in Alzheimer's disease or the heart in cardiomyopathy. The research deploys three integrated approaches:...
- Federal Project Grant Award Summary Fred Hutchinson Cancer Center received a $776,511 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion targeted for May 31, 2029. This award supports research to develop and validate a three-dimensional engineered hemogenic vascular niche model designed to elucidate the microenvironmental factors that promote hematopoietic stem...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Washington $2,647,494 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop computational and experimental models of myosin variants that determine how single amino acid variants affect myosin structure and function across multiple scales. The project integrates molecular and Brownian dynamics simulations of the chemo-mechanical cycle of β-myosin, generated from human crystal and...
- The National Heart, Lung and Blood Institute awarded the University of Washington $233,250 under CFDA 93.837 (Cardiovascular Diseases Research) on June 18, 2026, to conduct AI-guided structural biology research on CAV1.2, an L-type calcium channel critical to cardiac contraction and excitation-coupling in the heart. The research will develop an artificial-intelligence-informed platform for structural biology of the CAV1.2 C-terminal domain (CTD), a 571-residue segment whose three-dimensional...
- The National Heart Lung and Blood Institute awarded Brigham & Women's Hospital Inc. $402,750 under Project Grant R21HL184189 on April 1, 2026, to conduct integrative single-cell analysis of aging-associated changes in human hematopoietic stem cell heterogeneity. The award funds two specific aims: identifying age-associated changes in hematopoietic stem cells (HSCs) across eleven existing datasets and determining how consensus gene expression programs shape HSC heterogeneity and relate to...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $806,288 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to assess healthy food policies that influence the dietary sodium-to-potassium ratio and reduce cardiovascular disease burden in U.S. counties. The project, titled "Leveraging Existing and Accessible Data to Reduce Sodium Intake and Prevent Cardiovascular Diseases in U.S. Counties Through Community-Engaged Policy...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $1,233,682 on May 1, 2026, for research bridging basic and clinical science to prevent cardiovascular disease in diabetes under the Cardiovascular Diseases Research program (CFDA 93.837). The research addresses residual cardiovascular disease risk in youth and adults with type 1 and type 2 diabetes despite standard LDL-cholesterol-lowering interventions. The project investigates whether increased hepatic...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $188,786 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a K23 career development award focused on investigating sphingolipids as a cardiovascular disease risk factor in patients with kidney disease. The award funds career development and research training for an assistant professor in nephrology at the University of Washington to transition to an independent...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1.137883 million on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the dynamics and plasticity of the hematopoietic stem cell niche. The funded work defines niche dynamics and plasticity across development, regeneration, and hematological disease; uncovers the mechanisms regulating these processes; and develops approaches to enhance...
The National Heart, Lung, and Blood Institute awarded the University of Washington $777,814 on August 15, 2026, to develop computational methods for enhanced clinical use of single-cell data under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of novel analytical frameworks to extract clinically actionable biomarkers from single-cell data generated by flow cytometry and other clinical technologies. The project addresses three gaps in current methodology: generating clinically actionable biomarkers from single-cell data, tracking patient-specific cellular dynamics throughout clinical care, and integrating single-cell data with broader clinical inputs through multi-modal modeling. Specific aims include developing a novel biomarker generation framework using unsupervised clustering and self-supervised embedding models; establishing methods to track patient-specific cellular dynamics; and creating multi-modal approaches that combine single-cell data with additional clinical variables. The project leverages a unique data resource—a large-scale archive of raw flow cytometry files underlying blood count testing at a major U.S. medical center—to develop robust methods for enhanced use of the complete blood count, the most commonly collected blood test worldwide. The recipient will supplement this institutional data with multiple open-source clinical single-cell datasets reflecting diverse patient samples and clinical challenges to ensure methodologic generality. The University of Washington, Office of Sponsored Programs, is the recipient. Performance occurs in Seattle, Washington, with work extending through April 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $777.8k | 8/6/26 |